CTT Pharmaceutical Holdings, Inc.

CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company's technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered wafer, an orally administrable wafer comprising at least one physiologically acceptable film forming agent. The company was formerly known as Mindesta Inc. and changed its name to CTT Pharmaceutical Holdings, Inc. in July 2015. The company is based in Ottawa, Canada.

CTT Pharmaceutical Holdings, Inc. trades as CTTH on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$155,907 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

CTT Pharmaceutical Holdings, Inc. can be compared against peers such as Bionoid Pharma, Inc., BioTech Medics, Inc., Body and Mind Inc., Endexx Corporation, Galexxy Holdings, Inc., Herborium Group, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.66M, beta of 0.71, and return on equity of -282.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CTTH currently shows total debt of $18,814 and beta of 0.71. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: S-1/A (2026-05-29 00:00:00), S-1/A (2026-04-15 00:00:00), S-1 (2025-12-30 00:00:00), 4 (2025-12-17 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.cttpharmaceuticals.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.